BIP Capital Partners
Primary Menu
Skip to content
HOME
About us
OUR TEAM
OUR HISTORY
investment approach
INVESTMENT APPROACH
INVESTMENT CHARACTERISTICS
portfolio
SELECTED INVESTMENTS
SELECTED EXITS
News
CONTACT
Enzymotec reports 3rd quarter 2014 unaudited financial results
Post navigation
Previous Post
BIP invests in lifebrain AG, an Austrian-based medical diagnostic laboratory group
Next Post
Moleskine announces first nine months 2014 results
